γ-Secretase inhibitors and modulators for Alzheimer's disease

Journal of Neurochemistry

Volumn 120, Issue SUPPL. 1, 2012, Pages 89-98

  Wolfe, Michael S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

active site; allosteric sites; amyloid; chemical probes; docking site; protease

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ACETYLSALICYLIC ACID; AVAGACESTAT; BEGACESTAT; BENZODIAZEPINE; BMS 299897; CALPAIN; CAPROLACTAM SUCCINAMIDE; CHF 5074; DFK 167; ELN 318463; ELN 475516; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; IBUPROFEN; IMATINIB; INDOMETACIN; ISOCOUMARIN DERIVATIVE; JNJ 40418677; L 685458; MW 167; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PLACEBO; PROTEASOME INHIBITOR; SEMAGACESTAT; SULINDAC SULFIDE; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CANCER;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; PROTEASE INHIBITORS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84655164279     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07501.x     Document Type: Review

References (76)

1. Basi G. S., Hemphill S., Brigham E. F., et al. (2010) Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res. Ther. 2, 36.
2. Beher D., Fricker M., Nadin A., et al. (2003) In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. Biochemistry 42, 8133-8142. (Pubitemid 36858974)
3. Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I., and, Shearman M. S., (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419-43426. (Pubitemid 39390641)
4. Bihel F., Das C., Bowman M. J., and, Wolfe M. S., (2004) Discovery of a subnanomolar helical D-tridecapeptide inhibitor of γ-secretase. J. Med. Chem. 47, 3931-3933. (Pubitemid 38970954)
5. Citron M., Diehl T. S., Gordon G., Biere A. L., Seubert P., and, Selkoe D. J., (1996) Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc. Natl. Acad. Sci. USA 93, 13170-13175. (Pubitemid 26382788)
6. Das C., Berezovska O., Diehl T. S., Genet C., Buldyrev I., Tsai J. Y., Hyman B. T., and, Wolfe M. S., (2003) Designed helical peptides inhibit an intramembrane protease. J. Am. Chem. Soc. 125, 11794-11795. (Pubitemid 37175395)
7. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., and, Van Leuven F., (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390. (Pubitemid 28093512)
8. Dovey H. F., John V., Anderson J. P., et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173-181. (Pubitemid 32044380)
9. Eriksen J. L., Sagi S. A., Smith T. E., et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449. (Pubitemid 38063773)
10. Esler W. P., Kimberly W. T., Ostaszewski B. L., et al. (2000) Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428-434.
11. Esler W. P., Das C., Campbell W. A., et al. (2002a) Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat. Cell Biol. 4, E110-111.
12. Esler W. P., Kimberly W. T., Ostaszewski B. L., Ye W., Diehl T. S., Selkoe D. J., and, Wolfe M. S., (2002b) Activity-dependent isolation of the presenilin/γ-secretase complex reveals nicastrin and a γ substrate. Proc. Natl. Acad. Sci. USA 99, 2720-2725. (Pubitemid 34240527)
13. Esler W. P., Das C., and, Wolfe M. S., (2004) Probing pockets S2-S4' of the gamma-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorg. Med. Chem. Lett. 14, 1935-1938. (Pubitemid 38410867)
14. Fleisher A. S., Raman R., Siemers E. R., et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038.
15. Fraering P. C., Ye W., Strub J. M., et al. (2004) Purification and characterization of the human gamma-secretase complex. Biochemistry 43, 9774-9789. (Pubitemid 38993827)
16. Fraering P. C., Ye W., Lavoie M. J., Ostaszewski B. L., Selkoe D. J., and, Wolfe M. S., (2005) gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide binding site. J. Biol. Chem. 280, 41987-41996. (Pubitemid 43023167)
17. Funamoto S., Morishima-Kawashima M., Tanimura Y., Hirotani N., Saido T. C., and, Ihara Y., (2004) Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry 43, 13532-13540. (Pubitemid 39391154)
18. Fuwa H., Takahashi Y., Konno Y., et al. (2007) Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. ACS Chem. Biol. 2, 408-418. (Pubitemid 350001562)
19. Ghosh A. K., Gemma S., and, Tang J., (2008) beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 5, 399-408. (Pubitemid 351952491)
20. Gillman K. W., Starrett J. E., Parker M. F., et al. (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med. Chem. Lett. 1, 120-124.
21. Goedert M., and, Spillantini M. G., (2006) A century of Alzheimer's disease. Science 314, 777-781. (Pubitemid 44706636)
22. Green R. C., Schneider L. S., Amato D. A., Beelen A. P., Wilcock G., Swabb E. A., and, Zavitz K. H., (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
23. Haapasalo A., and, Kovacs D. M., (2011) The many substrates of presenilin/gamma-secretase. J. Alzheimers Dis. 25, 3-28.
24. He G., Luo W., Li P., et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-98.
25. Herreman A., Hartmann D., Annaert W., et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. Natl. Acad. Sci. USA 96, 11872-11877. (Pubitemid 29502825)
26. Higaki J., Quon D., Zhong Z., and, Cordell B., (1995) Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651-659.
27. Hyde L. A., McHugh N. A., Chen J., et al. (2006) Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-di hydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J. Pharmacol. Exp. Ther. 319, 1133-1143.
28. Imamura Y., Watanabe N., Umezawa N., Iwatsubo T., Kato N., Tomita T., and, Higuchi T., (2009) Inhibition of gamma-secretase activity by helical beta-peptide foldamers. J. Am. Chem. Soc. 131, 7353-7359.
29. Imbimbo B. P., Del Giudice E., Colavito D., et al. (2007) 1-(3′,4′-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)- cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822-830. (Pubitemid 350146064)
30. Imbimbo B. P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M., and, Windisch M., (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982-993.
31. Imbimbo B. P., Giardino L., Sivilia S., et al. (2010) CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 20, 159-173.
32. Kimberly W. T., LaVoie M. J., Ostaszewski B. L., Ye W., Wolfe M. S., and, Selkoe D. J., (2003) γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc. Natl. Acad. Sci. USA 100, 6382-6387. (Pubitemid 36666590)
33. Klafki H. W., Paganetti P. A., Sommer B., and, Staufenbiel M., (1995) Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci. Lett. 201, 29-32.
34. Klafki H., Abramowski D., Swoboda R., Paganetti P. A., and, Staufenbiel M., (1996) The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J. Biol. Chem. 271, 28655-28659. (Pubitemid 26374693)
35. Kopan R., and, Ilagan M. X., (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233.
36. Kornilova A. Y., Bihel F., Das C., and, Wolfe M. S., (2005) The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc. Natl. Acad. Sci. USA 102, 3230-3235. (Pubitemid 40328028)
37. Kounnas M. Z., Danks A. M., Cheng S., et al. (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780.
38. Kreft A., Harrison B., Aschmies S., et al. (2008) Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg. Med. Chem. Lett. 18, 4232-4236.
39. Kreft A. F., Martone R., and, Porte A., (2009) Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J. Med. Chem. 52, 6169-6188.
40. Kukar T., Prescott S., Eriksen J. L., Holloway V., Murphy M. P., Koo E. H., Golde T. E., and, Nicolle M. M., (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8, 54.
41. Kukar T. L., Ladd T. B., Bann M. A., et al. (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925-929.
42. Lanz T. A., Wood K. M., Richter K. E., et al. (2010) Pharmacodynamics and pharmacokinetics of the {gamma}-secretase inhibitor, PF-3084014. J. Pharmacol. Exp. Ther. 334, 269-277.
43. Li Y. M., Lai M. T., Xu M., et al. (2000a) Presenilin 1 is linked with gamma -secretase activity in the detergent solubilized state. Proc. Natl. Acad. Sci. USA 97, 6138-6143. (Pubitemid 30367536)
44. Li Y. M., Xu M., Lai M. T., et al. (2000b) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694. (Pubitemid 30428655)
45. Martone R. L., Zhou H., Atchison K., et al. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther. 331, 598-608.
46. May P., Altsteil L., Bender M., et al. (2002) Chronic treatment with a functional gamma-secretase inhibitor reduces Abeta burden and plaque pathology in PDAPP mice. Neurobiol. Aging 23, S133.
47. Mayer S. C., Kreft A. F., Harrison B., et al. (2008) Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J. Med. Chem. 51, 7348-7351.
48. Morohashi Y., Kan T., Tominari Y., et al. (2006) C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J. Biol. Chem. 281, 14670-14676. (Pubitemid 43855171)
49. Netzer W. J., Dou F., Cai D., et al. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl. Acad. Sci. USA 100, 12444-12449. (Pubitemid 37271579)
50. Peretto I., Radaelli S., Parini C., et al. (2005) Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 48, 5705-5720. (Pubitemid 41298345)
51. Petit A., Bihel F., Alves da Costa C., Pourquie O., Checler F., and, Kraus J. L., (2001) New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat. Cell Biol. 3, 507-511. (Pubitemid 32422088)
52. Pissarnitski D., (2007) Advances in gamma-secretase modulation. Curr. Opin. Drug Discov. Dev. 10, 392-402.
53. Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436-445. (Pubitemid 40105614)
54. Saito T., Suemoto T., Brouwers N., et al. (2011) Potent amyloidogenicity and pathogenicity of Abeta43. Nat. Neurosci. 2011, 2858.
55. Sato T., Dohmae N., Qi Y., et al. (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J. Biol. Chem. 278, 24294-24301; E-pub 22003 Apr 24221.
56. Sato T., Nyborg A. C., Iwata N., Diehl T. S., Saido T. C., Golde T. E., and, Wolfe M. S., (2006) Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry 45, 8649-8656. (Pubitemid 44078885)
57. Searfoss G. H., Jordan W. H., Calligaro D. O., et al. (2003) Adipsin: a biomarker of gastrointestinal toxicity mediated by a functional gamma secretase inhibitor. J. Biol. Chem. 278, 46107-46116. (Pubitemid 37432761)
58. Seiffert D., Bradley J. D., Rominger C. M., et al. (2000) Presenilin-1 and -2 are molecular targets for gamma -secretase inhibitors. J. Biol. Chem. 275, 34086-34091.
59. Shearman M. S., Beher D., Clarke E. E., et al. (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39, 8698-8704. (Pubitemid 30602778)
60. Shen J., Bronson R. T., Chen D. F., Xia W., Selkoe D. J., and, Tonegawa S., (1997) Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89, 629-639. (Pubitemid 27511773)
61. Siemers E., Skinner M., Dean R. A., Gonzales C., Satterwhite J., Farlow M., Ness D., and, May P. C., (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126-132. (Pubitemid 40923411)
62. Siemers E. R., Dean R. A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M. R., and, May P. C., (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 30, 317-325. (Pubitemid 350307310)
63. Stanton M. G., Hubbs J., Sloman D., et al. (2009) Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 755-758.
64. Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., and, Ihara Y., (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042-13052.
65. Tanzi R. E., and, Bertram L., (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555. (Pubitemid 40269768)
66. Van Broeck B., Chen J. M., Treton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M., and, Rowley A., (2011) Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 163, 375-389.
67. Weggen S., Eriksen J. L., Das P., et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216. (Pubitemid 33051236)
68. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Ozols V., Fauq A., Golde T. E., and, Koo E. H., (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278, 31831-31837. (Pubitemid 37048365)
69. Wolfe M. S., (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45, 7931-7939. (Pubitemid 43993216)
70. Wolfe M. S., (2008) Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 5, 391-398. (Pubitemid 351952492)
71. Wolfe M. S., Citron M., Diehl T. S., Xia W., Donkor I. O., and, Selkoe D. J., (1998) A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity. J. Med. Chem. 41, 6-9.
72. Wolfe M. S., Xia W., Moore C. L., Leatherwood D. D., Ostaszewski B., Donkor I. O., and, Selkoe D. J., (1999) Peptidomimetic probes and molecular modeling suggest Alzheimer's γ-secretases are intramembrane-cleaving aspartyl proteases. Biochemistry 38, 4720-4727.
73. Wong P. C., Zheng H., Chen H., et al. (1997) Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387, 288-292. (Pubitemid 27220764)
74. Wong G. T., Manfra D., Poulet F. M., et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882. (Pubitemid 38445862)
75. Yan X. X., Li T., Rominger C. M., Prakash S. R., Wong P. C., Olson R. E., Zaczek R., and, Li Y. W., (2004) Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. J. Neurosci. 24, 2942-2952. (Pubitemid 38410617)
76. Zhao B., Yu M., Neitzel M., et al. (2008) Identification of gamma-secretase inhibitor potency determinants on presenilin. J. Biol. Chem. 283, 2927-2938.